Julien Edeline

18.4k total citations · 5 hit papers
198 papers, 6.9k citations indexed

About

Julien Edeline is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, Julien Edeline has authored 198 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Oncology, 88 papers in Pulmonary and Respiratory Medicine and 87 papers in Hepatology. Recurrent topics in Julien Edeline's work include Hepatocellular Carcinoma Treatment and Prognosis (83 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (65 papers) and Pancreatic and Hepatic Oncology Research (38 papers). Julien Edeline is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (83 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (65 papers) and Pancreatic and Hepatic Oncology Research (38 papers). Julien Edeline collaborates with scholars based in France, United Kingdom and United States. Julien Edeline's co-authors include Étienne Garin, Yan Rolland, Jean‐Luc Raoul, Masatoshi Kudo, Richard S. Finn, Éveline Boucher, Ann‐Lii Cheng, Philippe Merle, Thomas Yau and Marc Pracht and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Hepatology.

In The Last Decade

Julien Edeline

188 papers receiving 6.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

2019 1.3k citations Richard S. Finn, Baek‐Yeol Ryoo et al. Journal of Clinical Oncology profile →
CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

2019 497 citations Thomas Yau, Richard S. Finn et al. Annals of Oncology profile →
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline

2019 285 citations Julien Edeline, John Primrose et al. Journal of Clinical Oncology profile →
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 278 citations Arndt Vogel, John Bridgewater et al. Annals of Oncology profile →
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

2022 135 citations Masatoshi Kudo, Philippe Merle et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Julien Edeline

Since Specialization

Citations

This map shows the geographic impact of Julien Edeline's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Edeline with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Edeline more than expected).

Fields of papers citing papers by Julien Edeline

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Edeline. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Edeline. The network helps show where Julien Edeline may publish in the future.

Co-authorship network of co-authors of Julien Edeline

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Edeline. A scholar is included among the top collaborators of Julien Edeline based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Edeline. Julien Edeline is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The impact of the time-of-day in the administration of immunotherapy and its efficacy in patients with advanced melanoma: A retrospective observational study 2025 ·Annales de Dermatologie et de Vénéréologie ·Mara De Amici, Érik Neveu, F. Poizeau, Julien Edeline, Thierry Lesimple, Emmanuel Oger, (unknown), A. Dupuy, (unknown)	0
2	139P KEYNOTE-966: 3-year follow-up for pembrolizumab (pembro) + gemcitabine and cisplatin (gem/cis) vs placebo (pbo) + gem/cis for patients (pts) with advanced biliary tract cancer (BTC) 2024 ·Annals of Oncology ·(unknown), Richard S. Finn, Changhoon Yoo, Zhenggang Ren, Junji Furuse, Robin Kate Kelley, Stephen L. Chan, Julien Edeline, Heinz‐Josef Klümpen, Thomas Yau, Chris Verslype, Masato Ozaka, Mohamed Bouattour, (unknown), Arndt Vogel, Juan W. Valle, Liis Starkopf, Usha Malhotra, (unknown), Shukui Qin	0
3	Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study. 2024 ·Journal of Clinical Oncology ·Richard S. Finn, Masatoshi Kudo, Ivan Borbath, Julien Edeline, Stéphane Cattan, Hans Van Vlierberghe, Chris Verslype, Daniel H. Palmer, Per Stål, Sadahisa Ogasawara, (unknown), Mark Karwal, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, (unknown), Ken Hatogai, Abby B. Siegel, Ann‐Lii Cheng, Jean‐Luc Van Laethem	2
4	An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma. 2024 ·Journal of Clinical Oncology ·Kevin Kim, Anwaar Saeed, Davendra Sohal, Julien Edeline, Jeong Heo, (unknown), (unknown), Guy Ungerechts	2
5	Factors associated with cancer treatment resumption after ICU stay in patients with solid tumors 2024 ·Annals of Intensive Care ·(unknown), (unknown), Benoît Painvin, Christophe Camus, Adel Maamar, Arnaud Gacouin, Charles Ricordel, Jean Reignier, Emmanuel Canet, Julien Edeline, Jean‐Marc Tadié	1
6	Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC). 2024 ·Journal of Clinical Oncology ·Philippe Merle, Jean-Marie Péron, Karine Le Malicot, (unknown), (unknown), Vincent Bourgeois, Eric Assénat, Jean‐Frédéric Blanc, Mohamed Bouattour, Yann Touchefeu, F. Khemissa Akouz, Éric Nguyen-Khac, Jean-Pierre Bronowicki, (unknown), (unknown), (unknown), Xavier Adhoute, Julien Edeline, Jean‐Charles Nault, Jean–Marc Phelip	1
7	Positivity of the KEYNOTE-394 but negativity of the KEYNOTE-240: differences in efficacy between Eastern and Western populations? 2023 ·Chinese Clinical Oncology ·Héloïse Bourien, Julien Edeline	1
8	Evolution of parenteral nutrition practices in a comprehensive cancer center: Comparative audits 2023 ·Bulletin du Cancer ·(unknown), (unknown), (unknown), Julien Edeline, Ronan Thibault, (unknown), Élodie Vauléon	2
9	Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma 2023 ·Current Oncology ·Victoria Foy, Mairéad G. McNamara, Juan W. Valle, Ángela Lamarca, Julien Edeline, Richard Hubner	1
10	Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes 2023 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), Olusola Olusesan Faluyi, Ángela Lamarca, Richard Hubner, Julien Edeline, Juan W. Valle, Mairéad G. McNamara	0
11	Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy 2023 ·British Journal of Cancer ·(unknown), Mairéad G. McNamara, Samuel Le Sourd, Ángela Lamarca, Astrid Lièvre, Héloïse Bourien, (unknown), Thomas Uguen, Richard Hubner, Juan W. Valle, Julien Edeline	3
12	Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study 2022 ·British Journal of Cancer ·(unknown), Vincent Hautefeuille, Édouard Auclin, Astrid Lièvre, David Tougeron, Matthieu Sarabi, Marine Gilabert, (unknown), Julien Edeline, Pascal Artru, Dominique Béchade, (unknown), Agnès Ducoulombier, Julien Taı̈eb, Simon Pernot	5
13	Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up breakdown → 2022 ·Annals of Oncology ·Arndt Vogel, John Bridgewater, Julien Edeline, Robin Kate Kelley, Heinz‐Josef Klümpen, David Malka, John Primrose, Lorenza Rimassa, Albrecht Stenzinger, Juan W. Valle, Michel Ducreux	278
14	ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma 2021 ·Cancers ·(unknown), (unknown), (unknown), Boris Campillo‐Gimenez, Samuel Le Sourd, Marc Pracht, Xavier Palard, Héloïse Bourien, (unknown), Thomas Uguen, Yan Rolland, Étienne Garin, Julien Edeline	14
15	Metastatic clear-cell renal cell carcinoma: Computed tomography texture analysis as predictive biomarkers of survival in patients treated with Nivolumab: NivoMics 01-Study 2020 ·European Urology Open Science ·(unknown), (unknown), B. Peyronnet, Julien Edeline, (unknown), Laurence Crouzet, Nathalie Rioux‐Leclercq, Brigitte Laguerre, Marc Pracht, (unknown), Karim Bensalah	1
16	Health‐related quality‐of‐life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE‐240 2020 ·Cancer ·Baek‐Yeol Ryoo, Philippe Merle, Amit S. Kulkarni, Ann‐Lii Cheng, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Bruno Daniele, Josephine M. Norquist, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Richard S. Finn, Masatoshi Kudo	25
17	Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role 2020 ·Cancers ·Stefania De Lorenzo, Francesco Tovoli, Alessandro Mazzotta, Francesco Vasuri, Julien Edeline, Deborah Malvi, Karim Boudjéma, Matteo Renzulli, Heithem Jeddou, Antonietta D’Errico, Bruno Turlin, Matteo Cescon, Thomas Uguen, Alessandro Granito, Astrid Lièvre, Giovanni Brandi	40
18	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial breakdown → 2019 ·Journal of Clinical Oncology ·Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, Masatoshi Kudo, Mohamed Bouattour, Ho Yeong Lim, В. В. Бредер, Julien Edeline, Yee Chao, Sadahisa Ogasawara, Thomas Yau, Marcelo Garrido, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Scot Ebbinghaus, Erluo Chen, Abby B. Siegel, Andrew X. Zhu, Ann‐Lii Cheng, (unknown)	1300
19	Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial 2018 ·JMIR Research Protocols ·Nikhil Chauhan, (unknown), Éveline Boucher, David Cosgrove, Julien Edeline, (unknown), Laura Kulik, (unknown), Riad Salem	31
20	Dosimetry Based on ^99mTc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with ⁹⁰Y-Loaded Glass Microspheres: Preliminary Results 2012 ·Journal of Nuclear Medicine ·Étienne Garin, Laurence Lenoir, Yan Rolland, Julien Edeline, H. Mesbah, Sophie Laffont, Philippe Porée, Bruno Clément, Jean‐Luc Raoul, É. Boucher	199

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact